MedGenome has expanded its sequencing capacity at its Foster City, Calif., headquarters laboratory, adding HiSeqX and NovaSeq 6000 platforms to meet the rising demands for Next Generation Sequencing (NGS) in research and clinical settings. The new additions increase MedGenome’s data-generation capability by a factor of five. Additionally, availability of a wide range of sequencing platforms gives MedGenome the flexibility to provide customized services at scale – thousands of whole genomes a month — and deliver high-quality data quickly at a competitive price. The NGS lab has also added sample-processing automation from Agilent to support the sequencing capacity.
“Adding the new platforms in our California lab gives us the throughput and scale to take on large genomic projects that are rapidly transforming the clinical trial landscape by enabling precision medicine and personalized therapy particularly in immuno-oncology, neurological disorders and rare diseases,” said Sam Santhosh, founder, chairman and global CEO of MedGenome. “Our ability to deliver high-quality data for large-scale genomics projects in a timely manner helps our clients to accelerate their preclinical and clinical research programs.”
As steady improvements continue in the treatment of multiple myeloma, it’s important for managed care executives to get out in front of the changes on the horizon.
“Several exciting new drugs are in the market or on the verge,” says Jeffrey Scott, MD, an oncologist and chief medical officer of Integra Connect. “This means that more patients are living longer and better, and treatment increasingly resembles chronic care.”
2,000. That’s the number of genomes, Genome Asia 100K have successfully sequenced. The non-profit organisation is collaborating to sequence a total of 100,000 Asian individuals’ genomes, in a bid to help accelerate population specific medical advances and precision medicine.
Why? Well, according to the projects Scientific Chairman, Professor Stephan Schuster, “The more we undertake research of Asia; we discover that it is genetically way more diverse than expected. We want to contribute to this effort to determine which variants are genetic variants in the population.”
MedGenome wants to develop research and diagnostics around rare diseases by looking at India’s population of 1.3 billion, and today the company announced funding of $30 million to further its mission. Sequoia Capital India and Sofina co-led the round, with participation from Zodius Capital and several individual investors.
Biomarkers are biological indicators of early disease detection (diagnostic), disease progression and outcome (prognostic), and response to therapy (predictive).